News

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.

Review top news and interview highlights from the week ending December 23, 2022.

Both REGENXBIO and Rocket Pharmaceuticals have announced trial updates in their gene therapy programs for rare diseases.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Invectys and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, announced the therapy and collaboration in June 2022.

Patients had an ORR of 83.8% with a median DOR of 15.7 months in data presented at the ASH 2022 meeting.

No dose-limiting toxicities or treatment-related serious adverse events were reported among 24 treated patients.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.

Review top news and interview highlights from the week ending December 16, 2022.

Half of wounds treated with the gene therapy had complete healing at both months 3 and 6 compared to 7% of placebo-treated wounds.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

New data from a phase 1/2 trial of BMS-986393 were presented at the 64th Annual ASH Meeting.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

Annualized bleed rate and FVIII infusion rates significantly decreased after infusion with the gene therapy.

Four of 17 patients who received UCART123v1.2 showed clinical benefit.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The complete metabolic response rate was 70% 3 months after infusion.

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.

Rates of complete response to the novel CAR-T varied from 67% to 75% across the 4 dosage levels tested.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

Among the 38 patients now dosed and evaluable, the ORR remains at 100%.

A complete response rate of 67% was reported and no treatment-limiting toxicity occurred.

A DCE analysis weighed gender-, age-, and disease-severity-specific annual costs as opposed to traditional cost-effectiveness models.

Additional data on 2 patients who developed persistent anemia suggests a genetic cause may be behind the serious adverse event.

Achilles Therapeutics presented updated data from CHIRON and THETIS at the 2022 ESMO immuno-oncology congress.